Evidence map›Paper›PMID 29096401›Full record

ArticleBritish journal of cancer2017

Inhibitor of DNA binding 2 is a novel therapeutic target for stemness of head and neck squamous cell carcinoma.

Woo Jin Bae, Bon Seok Koo, Sang Hyuk Lee, Jin Man Kim, Young Soo Rho, Jae Yol Lim, Jung Hwa Moon, Jae Hoon Cho, Young Chang Lim

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Woo Jin BaeDepartment of Otorhinolaryngology - Head and Neck Surgery, Research Institute of Medical Science, Konkuk University School of Medicine, No. 1, Hwayang-dong, Gwangin-gu, 120-1 Neungdong ro, Seoul 143-752, South Korea.
Bon Seok KooDepartment of Otolaryngology - Head and Neck Surgery, Cancer Research Institute, Research Institute for Medical Sciences and Pathology, Daejeon 301-721, South Korea.
Sang Hyuk LeeDepartment of Otorhinolaryngology - Head and Neck Surgery, Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, Seoul 110-746, South Korea.
Jin Man KimChungnam National University College of Medicine, Daejeon 301-721, South Korea.
Young Soo RhoDepartment of Otolaryngology - Head and Neck Surgery, Hallym University College of Medicine, Seoul 134-701, South Korea.
Jae Yol LimDepartment of Otorhinolaryngology, Yonsei University School of Medicine, Seoul 06273, South Korea.
Jung Hwa MoonDepartment of Otorhinolaryngology - Head and Neck Surgery, Research Institute of Medical Science, Konkuk University School of Medicine, No. 1, Hwayang-dong, Gwangin-gu, 120-1 Neungdong ro, Seoul 143-752, South Korea.
Jae Hoon ChoDepartment of Otorhinolaryngology - Head and Neck Surgery, Research Institute of Medical Science, Konkuk University School of Medicine, No. 1, Hwayang-dong, Gwangin-gu, 120-1 Neungdong ro, Seoul 143-752, South Korea.
Young Chang LimDepartment of Otorhinolaryngology - Head and Neck Surgery, Research Institute of Medical Science, Konkuk University School of Medicine, No. 1, Hwayang-dong, Gwangin-gu, 120-1 Neungdong ro, Seoul 143-752, South Korea.
Konkuk University · KRChungnam National University · KRHallym University · KRKorea Institute of Radiological and Medical Sciences · KRSungkyunkwan University · KRYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHead and neck squamous cell carcinomas (HNSCCs) are highly lethal epithelial tumours containing self-renewal cancer stem cells (CSCs). CSCs in HNSCCs are strongly associated with tumour initiation, invasion, and chemoradiation resistance. However, the important factors regulating stemness in HNSCCs remain unclear. Here, we investigated the molecular roles and clinical significance of inhibitor of DNA binding 2 (Id2) protein to determine if it constitutes a novel therapeutic target for ablating HNSCC cells with stemness.

methodsWe performed in vitro and in vivo studies of Id2 function and its effects on stemness using HNSCC cells. We also examined whether Id2 expression could be used as a prognostic indicator through immunohistochemical staining of 119 human HNSCC tumours.

resultsExpression of Id2 was higher in HNSCC cells with stemness compared with differentiated HNSCC cells. Overexpression of Id2 increased proliferation, self-renewal, and expression of the putative stemness marker CD44 in HNSCC cells in vitro and in vivo. In contrast, silencing of Id2 using short hairpin RNA attenuated the stemness phenotype of HNSCC cells by reducing self-renewal, CD44 expression, cisplatin chemoresistance, and xenograft tumourigenicity. Most importantly, increased expression of Id2 was closely associated with poorer post-treatment survival rates in HNSCC patients.

conclusionsInhibitor of DNA binding2 represents a novel and promising therapeutic target for treating and improving the clinical outcomes for patients with HNSCC.

Indexed as

AnimalsAntineoplastic AgentsCarcinoma, Squamous CellCell Line, TumorCell ProliferationCell Self RenewalCell SurvivalCisplatinDrug Resistance, NeoplasmFemaleGene ExpressionGene SilencingHead and Neck NeoplasmsHumansHyaluronan ReceptorsInhibitor of Differentiation Protein 2Antineoplastic AgentsCD44 protein, humanCisplatinHyaluronan ReceptorsID2 protein, humanInhibitor of Differentiation Protein 2

Identifiers

PMID29096401
PMCPMC5729481
OpenAlexW2765670423

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.